Current issue
Archive
About the Journal
About us
Aims and Scope
Indexing and Abstracting
Editorial Office
Open Access Policy
Publication Ethics
Contact
For Authors
Editorial Policy
Peer Review Policy
Manuscript Preparation Guidelines
Copyright & Licensing
Publication Fees
Fast-Track Paper Publication Option
Conflict Interest Guidance
Submit an Article
Special Issues
News & Editorials
“Fake,” “Predatory,” and “Pseudo” Journals: Charlatans Threatening Trust in Science
Shifting the Journal submission-review system to the Editorial System Manuscript December 27, 2017.
ORIGINAL ARTICLE
Exploration of the Beta-Actin DNA Integrity Index as Early Genetic Marker of Presence of Breast Cancer
1
Department of Biology, College of Science, University of Anbar, Ramadi, IRAQ
2
Department of Biotechnology, College of Science, University of Anbar, Ramadi, IRAQ
3
College of Medicine, University of Falluja, Anbar, IRAQ
Online publication date: 2020-02-15
Publication date: 2020-02-15
Electron J Gen Med 2020;17(2):em188
KEYWORDS
ABSTRACT
Background:
Circulating cell-free DNA (cfDNA) and its integrity index can be a fast and non-invasive (liquid biopsy) biomarker, this provides significant additional data for diagnosis, prognosis and therapy stratification in cancer patient.
Methods:
The circulating tumor DNA (ctDNA) concentration and integrity was investigated in the plasma from patients with breast cancer by a quantitative polymerase chain reaction (qPCR) and their diagnostic value for breast cancer etiology was evaluated Plasma samples were collected from 55 patients 40 patients with breast cancer, 5 patients each with other type of cancer (ovarian cancer, colon cancer, stomach cancer) and 20 healthy controls. Real-time PCR of β-actin gene were investigated using two primer sets (400 and 100bp) to amplify different DNA fragment lengths. The DNA integrity index was calculated as the ratio of q-PCR results of β-actin 400bp/100.
Results:
In all cancer patients the DNA concentrations were significantly higher p<0.0001, than those of the control group. The plasma DNA integrity was statistically significantly lower in breast cancer and colon cancer than the control groups (p<0.001).
Conclusion:
The plasma DNA concentration and integration test can serve as a new diagnostic marker for detection and monitoring of patients with breast cancer and colon cancer.
Circulating cell-free DNA (cfDNA) and its integrity index can be a fast and non-invasive (liquid biopsy) biomarker, this provides significant additional data for diagnosis, prognosis and therapy stratification in cancer patient.
Methods:
The circulating tumor DNA (ctDNA) concentration and integrity was investigated in the plasma from patients with breast cancer by a quantitative polymerase chain reaction (qPCR) and their diagnostic value for breast cancer etiology was evaluated Plasma samples were collected from 55 patients 40 patients with breast cancer, 5 patients each with other type of cancer (ovarian cancer, colon cancer, stomach cancer) and 20 healthy controls. Real-time PCR of β-actin gene were investigated using two primer sets (400 and 100bp) to amplify different DNA fragment lengths. The DNA integrity index was calculated as the ratio of q-PCR results of β-actin 400bp/100.
Results:
In all cancer patients the DNA concentrations were significantly higher p<0.0001, than those of the control group. The plasma DNA integrity was statistically significantly lower in breast cancer and colon cancer than the control groups (p<0.001).
Conclusion:
The plasma DNA concentration and integration test can serve as a new diagnostic marker for detection and monitoring of patients with breast cancer and colon cancer.
REFERENCES (21)
1.
Abdulrahman GO, Rahman GA. Epidemiology of breast cancer in Europe and Africa. Journal of Cancer Epidemiology. 2012;2012:915610. https://doi.org/10.1155/2012/9... PMid:22693503 PMCid:PMC3368191.
2.
Jemal A, Bray F, Center, MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011;61(2):69-90. https://doi.org/10.3322/caac.2... PMid:21296855.
3.
Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C. The decline in breast cancer mortality in Europe: an update (to 2009). The Breast. 2012;21(1):77-82. https://doi.org/10.1016/j.brea... PMid:21906943.
4.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2015;65(2):87-108. https://doi.org/10.3322/caac.2... PMid:25651787.
5.
Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clinica Chimica Acta. 2010;411(23-24):1869-74. https://doi.org/10.1016/j.cca.... PMid:20816948.
6.
El-Gayar D, El-Abd N, Hassan N, Ali R. Increased free circulating DNA integrity index as a serum biomarker in patients with colorectal carcinoma. Asian Pac J Cancer Prev. 2016;17(3):939-44. https://doi.org/10.7314/APJCP.... PMid:27039817.
7.
Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, ... Shih IM. Increased plasma DNA integrity in cancer patients. Cancer Research. 2003;63(14):3966-8.
9.
McPherson K, Steel C, Dixon JM. ABC of breast diseases: breast cancer—epidemiology, risk factors, and genetics. BMJ: British Medical Journal. 2000;321(7261):624. https://doi.org/10.1136/bmj.32... PMid:10977847 PMCid:PMC1118507.
10.
Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Norden toft I, ... Hamilton-Dutoit S. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016;65(4):625-34. https://doi.org/10.1136/gutjnl... PMid:25654990.
11.
Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of breast tumor progression by integrity of free circulating DNA in serum. Journal of Clinical Oncology. 2006;24(26):4270-6. https://doi.org/10.1200/JCO.20... PMid:16963729.
12.
Salvianti F, Giuliani C, Petrone L, Mancini I, Vezzosi V, Pupilli C, Pinzani P. Integrity and quantity of total cell-free DNA in the diagnosis of thyroid cancer: Correlation with cytological classification. International Journal of Molecular Sciences. 2017;18(7):1350. https://doi.org/10.3390/ijms18... PMid:28672797 PMCid:PMC5535843.
13.
Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, ... Hamilton-Dutoit S. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. (2016);65(4):625-34. https://doi.org/10.1136/gutjnl... PMid:25654990.
14.
Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PloS One. 2015;10(7):e0133830. https://doi.org/10.1371/journa... PMid:26207909 PMCid:PMC4514648.
15.
Chudasama DY, Aladag Z, Felicien MI, Hall M, Beeson J, Asadi N, ... Anikin, VB. Prognostic value of the DNA integrity index in patients with malignant lung tumors. Oncotarget. 2018;9(30):21281-8. https://doi.org/10.18632/oncot... PMid:29765538 PMCid:PMC5940399.
16.
Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, ... Frost P. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991;252(5006):706-9. https://doi.org/10.1126/scienc... PMid:2024123.
17.
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer F O, Hesch R D, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Research. 2001;61(4):1659-65.
18.
Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Research. 1977;37(3):646-50.
19.
Guo C. Liu S. Wang J, Sun MZ, Greenaway FT. ACTB in cancer. Clinica Chimica Acta. 2013;417(8):39-44. https://doi.org/10.1016/j.cca.... PMid:23266771.
20.
Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, ... Toppan P. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Annals of Surgical Oncology. 2011;18(9):2461-8. https://doi.org/10.1245/s10434... PMid:21416156.
21.
Sun W, Sun Y, Zhu M, Wang Z, Zhang H, Xin Y, ... Liu Y. The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. Oncology Reports. 2014;31(3):1466-72. https://doi.org/10.3892/or.201... PMid:24378613.
Share
RELATED ARTICLE
| eISSN: | 2516-3507 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
